Sanofi-Aventis U.S

Company snapshot

Sanofi-Aventis U.S maintains 117 tracked programs across Dermatitis atopic, Cancer, Immune system diseases, Asthma, Chronic Obstructive Pulmonary Disease, Chronic rhinosinusitis with nasal polyps, Respiratory tract diseases, Nervous system diseases, Multiple Sclerosis, Multiple sclerosis, multiple sclerosis, Alpha-1 Antitrypsin Deficiency (AATD) Emphysema. Momentum score: n/a/100 (30-day delta: n/

• 22 approved product(s) across US/EU regulatory metadata.
• 117 active pipeline program(s) linked via ClinicalTrials.gov.
• 117 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Sanofi-Aventis U.S. Not investment advice.

• Peer + 0 momentum

  Teva Pharma

  TA overlap score 50

• Peer + 0 momentum

  Novartis India

  TA overlap score 50

• Peer + 0 momentum

  AstraZeneca

  TA overlap score 50

• Peer + 0 momentum

  Regeneron UK

  TA overlap score 40

• Peer + 0 momentum

  MedImmune

  TA overlap score 21.8

Recent activity

Latest pipeline, patent, and corporate events for Sanofi-Aventis U.S.

1. Jun 8, 2026 Clinical update

   SAD18184/MAD18185 — Phase 1

2. Jun 8, 2026 Clinical update

   PSK00010 — Phase 3

3. Jun 8, 2026 Clinical update

   PKM23567 — Phase 1

4. Jun 8, 2026 Clinical update

   PDY17892 — Phase 1

5. Jun 8, 2026 Clinical update

   EFC17872 — Phase 3

View all clinical trial activity →

• What is Sanofi-Aventis U.S?

  Sanofi-aventis Healthcare Pty is a pharma organization headquartered in Sydney, AU. Primary therapeutic focus areas include Dermatitis atopic, Cancer, Immune system diseases, Asthma, Chronic Obstructive Pulmonary Disease. NovaPharmaNews links 117 clinical program(s), 21 drug prof

• Is Sanofi-Aventis U.S publicly traded?

  Sanofi-Aventis U.S appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Sanofi-Aventis U.S develop or market?

  We link 148 drug profile(s) where Sanofi-Aventis U.S is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/sanofi-pharma-bristol-myers-squibb#company-drugs.

• What are the latest developments for Sanofi-Aventis U.S?

  In the last 12 months our linked public records show 117 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Sanofi-Aventis U.S focus on?

  Sanofi-Aventis U.S focuses on Dermatitis atopic, Cancer, Immune system diseases based on our analysis of their pipeline programs and drug development activities.